Select a cancer type to view all clinical trials for that cancer, or view all currently open clinical trials below.
All Current Clinical Trials
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| MTX-TROP2-302 | Multi-Cancers | MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors | Immunotherapy | TROP2 targeting. Low volume disease only. | Open - Recruiting | Myeloid Therapeutics | NCT05969041 | Enquire Now |
| DM002001 | Multi-Cancers | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | NCT06751329 | Enquire Now |
| SR-8541A-001 | Multi-Cancers | Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors | Targeted | PO small molecule ENPP1 inhibitor in combination of Nivolumab/Pembrolizumab (Introduction of ICI is after C2 onwards) | Open - Recruiting | Stingray Therapeutics | NCT06063681 | Enquire Now |
| SSGJ-709-101 | Multi-Cancers | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors | Immunotherapy | Anti-PD-1 and anti-LAG-3 bispecific antibody | Open - Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07016490 | Enquire Now |
| NXT-9216-101 | Multi-Cancers | A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair | Targeted | PO Small molecule inhibitor of WRN helicase activity - MSI-H/dMMR tumours | Open - Recruiting | Nimbus Wadjet, Inc. | NCT06898450 | Enquire Now |
| HRS-5041-103 | Prostate Cancer | A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | Targeted | PO AR-PROTAC molecule - AR degrader | Open - Recruiting | Atridia Pty Ltd | NCT06830850 | Enquire Now |
| ON-5001 | Multi-Cancers | A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas | Injectable Lesion | Intratumoral (IT) injection. PC7A nanoparticles loaded with cGAMP. Stimulator of interferon genes. | Closed | OncoNano Medicine, Inc. | NCT06022029 | Enquire Now |
| SRG-514-01 | Breast Cancer | A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery | NSAID Gel | Intraoperative administration into breast cavity. Newly diagnosed BCa patients. Gel Ketorolac (NSAID by blocking cyclooxygenase (COX) enzymes). | Open - Recruiting | SURGE Therapeutics | NCT06300411 | Enquire Now |
| A001 | Multi-Cancers | A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies | Immunotherapy | CDH17 targeting IO. | Closed | Arbele Pty Ltd | NCT05411133 | Enquire Now |
| CP-IVX001 | Multi-Cancers | A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Injectable Lesions | Ovarian, Gastric and CRC only. Must have Injectable lesions. Intratumoral injection. Live EchoVirus, No GMO component. | Open - Recruiting | ImmVirx PtyLtd | NCT05427487 | Enquire Now |
| CP-AU-007-01 | Multi-Cancers | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Immunotherapy | IL-2 and Inhibits IL-2Rα Binding in combo. | Open - Recruiting | Aulos Bioscience, Inc. | NCT05267626 | Enquire Now |
| DCSZ11-101 | Multi-Cancers | A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Immunotherapy | Anti-CD93 monoclonal antibody, as a monotherapy and in combination with pembro. | Closed | DynamiCure Biotechnology | NCT05785754 | Enquire Now |
| HMBD-001-103 | Multi-Cancers | A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers | Targeted | Humanized IgG1 anti-HER3 monoclonal antibody + Combo treatment for squamous HER3 Mutation. | Open - Recruiting | Hummingbird Bioscience | NCT05910827 | Enquire Now |
| PSMA-007-001 | Castrate-Resistant Prostate Cancer | A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Immunotherapy | PSMA targeting BiTE. | Open - Recruiting | Janux Therapeutics | NCT05519449 | Enquire Now |
| GRWD5769-ST-01 | Multi-Cancers | A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination With Anticancer Treatments in Patients With Solid Malignancies | Immunotherapy | Novel EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1). | Open - Recruiting | Grey Wolf Therapeutics Pty Ltd | NCT06923761 | Enquire Now |
| NST-628-001 | Multi-Cancers | A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors | Targeted | MAPK pathway mutated/dependent advanced solid tumors. | Open - Recruiting | Nested Therapeutics, Inc | NCT06326411 | Enquire Now |
| AWT020-001 | Multi-Cancers | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer | Immunotherapy | Anti-PD1 IL-2 BiTE. | Open - Recruiting | Anwita Biosciences | NCT06092580 | Enquire Now |
| INI-4001-101 | Multi-Cancers | An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours | Immunotherapy | Small molecule TLR7/8 agonist. | Open - Recruiting | Inimmune Corporation | NCT06302426 | Enquire Now |
| PTT-4256-01 | Multi-Cancers | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| YH32367-101 | Multi-Cancers | A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors | Targeted | HER2/4-1BB bispecific antibody. Targets HER2 and h4-1BB and binds to both targets. | Open - Recruiting | Yuhan Corporation | NCT05523947/a> | Enquire Now |
| D3S-002-100 | Multi-Cancers | A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations | Targeted | Mitogen-Activated Protein Kinase (MAPK) pathway mutation targeting. | Open - Recruiting | D3 Bio (Wuxi) Co., Ltd | NCT05886920 | Enquire Now |
| JS125-001-I | Multi-Cancers | A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ47156 Monotherapy and in Combination With Other Anti-Tumor Therapies in Patients With Advanced Malignant Solid Tumors | Targeted | MSI high Colorectal Ca. PO in IV combo. IP selectively inhibiting the enzymatic activity of HDAC. | Closed | Shanghai Junshi Bioscience Co., Ltd. | NCT06571422 | Enquire Now |
| BM230-01 | Multi-Cancers | A Phase I, Multicenter, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Patients With Advanced Solid Tumors | Targeted | All with HER2. Subcutaneous injection. Bispecific antibody that specifically activates NK cells. Strongly binds to HER2 and CD16A. | Open - Recruiting | Suzhou Biomissile Pharmaceuticals Co., Ltd. | NCT06644300 | Enquire Now |
| ADCE-T02-01 | Multi-Cancers | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| AMT-116-01 | Multi-Cancers | First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti-CD44v9 Antibody-Drug Conjugate | Open - Recruiting | Multitude Therapeutics Inc. | NCT05725291 | Enquire Now |
| AMT-253-01 | Multi-Cancers | First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti MUC18 Antibody-Drug Conjugate | Open - Recruiting | Multitude Therapeutics (Australia) Pty Ltd | NCT05906862 | Enquire Now |